Fisher & Paykel Healthcare Corporation Limited logo

FPH enters into construction contract for fifth NZ building

Property5 March 2025FPHHealthcare

News Release
STOCK EXCHANGE LISTINGS: NEW ZEALAND (FPH), AUSTRALIA (FPH)


Fisher & Paykel Healthcare enters into construction contract for fifth building in New

Zealand


Auckland, New Zealand, 6 March 2025 – Fisher & Paykel Healthcare Corporation Limited

announced today that it has signed a building construction contract with Dominion Constructors

Limited for the fifth building on its East Tāmaki campus in Auckland.


"We are excited to add this new building to complete our East Tāmaki campus," said Andy Niccol,

Chief Operating Officer. “This project is a purposeful investment in infrastructure to ensure we have

the necessary capacity and resources in New Zealand to progress our pipeline of innovative

products and therapies.”


With a total gross floor area of about 28,000m

2

, the new building will showcase a cohesive blend of

spaces for research and development, manufacturing and distribution. The building’s design will

reflect the company’s culture of collaboration, with an open-plan work environment. The estimated

total cost of the new building is expected to be approximately NZ$250 million.


The 42-hectare East Tāmaki site currently has over 3,900 employees, and the new building will

accommodate the company’s expected growth in Auckland over the next five years. Earthworks

have been largely completed and construction will start later this month, with the facility expected

to be operational in 2027.


The company also recently submitted a private plan change application for its additional New

Zealand campus at Karaka, Auckland, to accommodate growth over the longer term.





An artist’s rendering of the fifth building on the company’s East Tāmaki campus.









About Fisher & Paykel Healthcare

Fisher & Paykel Healthcare is a leading designer, manufacturer and marketer of products and

systems for use in acute and chronic respiratory care, surgery and the treatment of obstructive

sleep apnea. The company’s products are sold in over 120 countries worldwide. For more

information about the company, visit our website www.fphcare.com.


Contacts:

Media Investors

Karen Knott

GM Corporate Communications

karen.knott@fphcare.co.nz

+64 (0) 21 713 911

Dan Adolph

Head of Investor Relations

daniel.adolph@fphcare.co.nz

+64 (0) 22 511 4050


Authorised by Fisher & Paykel Healthcare Corporation Limited’s Board of Directors.

Data sourced from publicly available filings. Our datasets may not be complete. Automated analysis can produce errors. If you believe any data on this page is incorrect, please contact us at hello@nzxplorer.co.nz. For informational purposes only. Not investment advice.

Other issuers discussed similar conditions around this time

Matched by meaning across NZX announcement text, not keywords — based on our semantic index of announcement bodies.